Kyverna to File FDA Submission for SPS CAR‑T Therapy
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Kyverna Therapeutics reported a one‑time personalized CAR‑T cell therapy that improved mobility and reduced disability in SPS patients in a presented study.
- Kyverna plans to submit an FDA NDA for the therapy by mid‑2026, aiming to become the first approved treatment for stiff person syndrome.
- CAR‑T technology, traditionally limited to hematologic cancers, is now being repurposed for autoimmune diseases, reflecting a broader industry shift.
Why it matters: Patients with stiff person syndrome gain a disease‑modifying therapy as Kyverna files by mid‑2026, while rivals lose a market gap and the move accelerates CAR‑T expansion into autoimmunity.
Ask SkimNews
